Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Cash and cash equivalents consisted of the following (in thousands):

	September 30, 2016		December 31, 2015
Cash	$	92,620	$	75,685
Money market funds		105,663		77,639
Total cash and cash equivalents	$	198,283	$	153,324

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	September 30, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	118,291	$	547	$	(7	)	$	118,831
Bond and mutual funds		23,049		152		—			23,201
Equity investments		125		95		—			220
Total investments	$	141,465	$	794	$	(7	)	$	142,252

	December 31, 2015
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	126,522	$	54	$	(473	)	$	126,103
Certificate of deposits		8,217		—		(2	)		8,215
Bond and mutual funds		25,052		—		—			25,052
Equity investments		126		71		—			197
Total investments	$	159,917	$	125	$	(475	)	$	159,567

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2016		December 31, 2015
Preclinical and clinical trial accruals	$	30,746	$	27,973
Payroll and related accruals		12,304		13,535
Professional services		1,730		1,662
Other		6,968		4,762
Total accrued liabilities	$	51,748	$	47,932